Umbilical cord blood transplantation: the first 25 years and beyond.

This year marks the 25th anniversary of the first umbilical cord blood (UCB) transplantation (UCBT) performed in France in a child with Fanconi Anemia (FA). Over the last 25 years, the field of UCB banking and transplantation has grown exponentially. Over 600 000 UCB units have been stored for transplantation worldwide, and .30 000 UCBTs have been performed. UCB serves as an alternative stem cell source; only 30% of patients who require an allograft will have a human leukocyte antigen (HLA)-matched sibling donor. Despite .20 million adult volunteer donors in the National Marrow Donor Program and affiliated registries, many patients, particularly patients of diverse racial/ethnic backgrounds, will not have a suitably matched, unrelated volunteer donor identified in the required time period. UCB has extended access to transplantation, especially to patients of racial and ethnic minorities, and is rapidly available. In this review, the scientific basis of UCBT is discussed, the historic first UCBT is revisited, and recent pediatric and adult UCBT outcome data are presented. Strategies for future improvement include: utilization of UCB expansion, ex vivo and in vivo homing techniques, in vivo nurturing procedures, selection of the optimal UCB unit, and enhancement of immune recovery.

[1]  J. Wagner,et al.  Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. , 2013, Blood.

[2]  Mark Munsell,et al.  Cord-blood engraftment with ex vivo mesenchymal-cell coculture. , 2012, The New England journal of medicine.

[3]  J. Kurtzberg,et al.  Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  H. Broxmeyer,et al.  Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis , 2012, Nature Medicine.

[5]  F. Appelbaum Pursuing the goal of a donor for everyone in need. , 2012, The New England journal of medicine.

[6]  C. Solano,et al.  Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen , 2012, Bone Marrow Transplantation.

[7]  E. Shpall,et al.  Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. , 2012, Experimental hematology.

[8]  J. Ritz,et al.  Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  A. Fischer,et al.  Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? , 2012, Blood.

[10]  K. Ballen,et al.  Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. , 2012, Blood.

[11]  G. Daley,et al.  The promise of induced pluripotent stem cells in research and therapy , 2012, Nature.

[12]  J. Ritz,et al.  Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. , 2011, Blood.

[13]  R. Larson,et al.  Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. , 2011, Blood.

[14]  J. Klein,et al.  Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. , 2011, The Lancet. Oncology.

[15]  E. Gluckman Milestones in umbilical cord blood transplantation. , 2011, Blood reviews.

[16]  J. Kurtzberg,et al.  Family-directed umbilical cord blood banking , 2011, Haematologica.

[17]  G. Papanicolaou,et al.  Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  J. Wagner,et al.  Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[20]  S. Witting,et al.  Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. , 2011, Blood.

[21]  J. Ritz,et al.  Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis , 2011, Bone Marrow Transplantation.

[22]  H. Broxmeyer,et al.  Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice. , 2011, Blood cells, molecules & diseases.

[23]  James M. Harris,et al.  Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. , 2011, Cell stem cell.

[24]  A. Scaradavou,et al.  How I treat: the selection and acquisition of unrelated cord blood grafts. , 2011, Blood.

[25]  J. Passweg,et al.  Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia , 2011, Haematologica.

[26]  Colleen Delaney,et al.  Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. , 2010, Blood.

[27]  J. Wagner,et al.  Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. , 2010, Blood.

[28]  J. Klein,et al.  Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  M. V. D. van den Brink,et al.  Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  H. Azuma,et al.  The impact of anti-HLA antibodies on unrelated cord blood transplantations. , 2010, Blood.

[31]  F. Locatelli,et al.  Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. , 2010, Blood.

[32]  Anthony E. Boitano,et al.  Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells , 2010, Science.

[33]  J. Wagner,et al.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.

[34]  H. Broxmeyer,et al.  Cord Blood Hematopoietic Cell Transplantation , 2010 .

[35]  A. Scaradavou,et al.  Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. , 2010, Blood.

[36]  Colleen Delaney,et al.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution , 2010, Nature Medicine.

[37]  H. Broxmeyer Will iPS cells enhance therapeutic applicability of cord blood cells and banking? , 2010, Cell stem cell.

[38]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  J. Smits,et al.  Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies , 2009, Proceedings of the National Academy of Sciences.

[40]  H. Broxmeyer,et al.  Experimental basis of cord blood transplantation , 2009, Bone Marrow Transplantation.

[41]  M. Mohty,et al.  Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies , 2009, Current opinion in oncology.

[42]  I. Millán,et al.  Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor , 2009, Bone Marrow Transplantation.

[43]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  J. Wagner,et al.  Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units , 2009, Bone Marrow Transplantation.

[45]  M. Labopin,et al.  KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia , 2009, Leukemia.

[46]  S. Asano,et al.  Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  J. Wagner,et al.  Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. , 2008, Blood.

[48]  M. Gobbi,et al.  Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. , 2008, The Lancet. Oncology.

[49]  J. Wagner,et al.  Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  K. Pollok,et al.  Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. , 2007, Stem cells and development.

[51]  J. Klein,et al.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study , 2007, The Lancet.

[52]  W. Hwang,et al.  A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  S. Asano,et al.  Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. , 2007, Blood.

[54]  H. Broxmeyer,et al.  Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26 , 2004, Science.

[55]  S. Chevret,et al.  Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. , 2004, Experimental hematology.

[56]  J. Wagner,et al.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. , 2003, Blood.

[57]  Alan D. D'Andrea Fanconi anemia , 2003, Current Biology.

[58]  J Wagner,et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. , 2002, Blood.

[59]  J. Wagner,et al.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. , 2001, The New England journal of medicine.

[60]  A. Zander,et al.  Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. , 2001, Blood.

[61]  F Locatelli,et al.  Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. , 1999, Blood.

[62]  J. Adamson,et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.

[63]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[64]  J. Wagner,et al.  Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. , 1996, Blood.

[65]  J. Kurtzberg,et al.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.

[66]  D. Bodine,et al.  Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes , 1995, The Journal of experimental medicine.

[67]  J. Klein,et al.  Bone marrow transplantation for Fanconi anemia. , 1995, Blood.

[68]  J. Wagner,et al.  Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease , 1995, The Lancet.

[69]  J. Dick,et al.  Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. , 1994, Blood.

[70]  H. Broxmeyer,et al.  Haemopoietic stem/progenitor cell transplant in Fanconi anaemia using HLA‐matched sibling umbilical cord blood cells , 1993, British journal of haematology.

[71]  H. Broxmeyer,et al.  Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM: An effect enhanced by cord blood plasma , 1993 .

[72]  J. Wagner,et al.  Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Wagner,et al.  Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. , 1992, Blood.

[74]  D. Williams,et al.  Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential. , 1991, Blood.

[75]  H. Broxmeyer,et al.  Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia , 1990, Transfusion.

[76]  J. Kurtzberg,et al.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.

[77]  H. Broxmeyer,et al.  Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[78]  E. Gluckman,et al.  Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation , 1983, British journal of haematology.

[79]  L. Freedman,et al.  Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries , 2011, Bone Marrow Transplantation.

[80]  M. Robin,et al.  Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT , 2011, Leukemia.

[81]  B. Yeap,et al.  Double unrelated reduced-intensity umbilical cord blood transplantation in adults. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[82]  ohn,et al.  The GRAFT-VERSUS-HOST DISEASE IN CHILDREN WHO HAVE RECEIVED A CORD-BLOOD OR BONE MARROW TRANSPLANT FROM AN HLA-IDENTICAL SIBLING , 2000 .

[83]  H. Broxmeyer,et al.  Enrichment, characterization, and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. , 1993, Blood.

[84]  J. Kurtzberg,et al.  Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. , 1991, Blood cells.

[85]  J. Kurtzberg,et al.  Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. , 1990, International journal of cell cloning.

[86]  R. Ellison ADULTS WITH ACUTE LEUKEMIA. , 1964, Acta - Unio Internationalis Contra Cancrum.